Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies.
The company was incorporated in 2021 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 30, 24 | -0.09 Decreased by -61.48% | - |
| Jun 30, 24 | -0.15 Increased by +27.97% | - |
| Mar 31, 24 | -0.16 Decreased by -119.66% | - |
| Dec 31, 23 | -0.05 Decreased by -16.75% | - |
| Sep 30, 23 | -0.05 Decreased by -1.52 K% | - |
| Jun 30, 23 | -0.21 Decreased by -4.18 K% | - |
| Mar 31, 23 | -0.07 Decreased by -334.15% | - |
| Dec 31, 22 | -0.04 Decreased by -183.21% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -4.23 M Decreased by -1.17 K% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.45 M Decreased by -17.02% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | N/A Decreased by N/A% | -2.30 M Increased by +5.69% | - - |
| Dec 31, 23 | N/A - | -282.76 K - | - - |
| Sep 30, 23 | N/A - | -334.03 K - | - - |
| Jun 30, 23 | 0.00 - | -2.09 M - | Decreased by N/A% - |
| Mar 31, 23 | 0.00 - | -2.44 M - | Decreased by N/A% - |